NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIDCD E-043-2016-0-GB-01 MICRORNAS AND METHODS OF THEIR USE GB EP 17712348.6 Issued
NIDCD E-043-2016-0-NL-01 MICRORNAS AND METHODS OF THEIR USE NL EP 17712348.6 Issued
NIDCD E-043-2016-0-EP-04 MICRORNAS AND METHODS OF THEIR USE EP National Stage 17712348.6 Issued
NIDCD E-043-2016-0-DE-01 MICRORNAS AND METHODS OF THEIR USE DE EP 17712348.6 Issued
NIDCD E-043-2016-0-FR-01 MICRORNAS AND METHODS OF THEIR USE FR EP 17712348.6 Issued
NIDCD E-043-2016-0-IT-01 MICRORNAS AND METHODS OF THEIR USE IT EP 17712348.6 Issued
NIDCD E-043-2016-0-IE-01 MICRORNAS AND METHODS OF THEIR USE IE EP 17712348.6 Issued
NIDCD E-043-2016-0-BE-01 MICRORNAS AND METHODS OF THEIR USE BE EP 17712348.6 Issued
NCI E-131-2016-0-AU-03 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO AU National Stage 2017254645 Issued
NIAID E-142-2016-0-US-04 FRANCISELLA LIPIDS AS BROAD ANTI-INFLAMMATORY THERAPEUTICS AND ASSOCIATED METHODS OF USE US National Stage 16/091,768 11529312 Issued PDF
NCATS E-240-2011-0-US-04 Human Galactokinase Inhibitors For The Treatment Of Galactosemia And Cancers US CON 16/152,735 10471061 Issued PDF
NCI E-132-2016-2-US-02 USE OF HETERODIMERIC IL-15 IN ADOPTIVE CELL TRANSFER US National Stage 16/091,967 Abandoned
NIAID E-118-2016-0-EP-08 Live Attenuated Zika Virus Vaccine EP National Stage 17714066.2 Abandoned
NIMH E-206-2017-0-PCT-02 SYSTEMS AND METHODS FOR PROBING IN-VIVO METABOLITE RELAXATION BY LINEAR QUANTIFICATION OF SPATIALLY MODULATED MAGNETIZATION PCT PCT PCT/US2018/054340 Expired
NIAID E-052-2017-4-HK-87 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection HK DIV 42021042265.5 Pending
NIAID E-128-2016-0-US-05 MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONOVIRUSES US National Stage 16/091,005 11041170 Issued PDF
NIDCD E-043-2016-0-IN-05 MICRORNAS AND METHODS OF THEIR USE IN National Stage 201817037296 Issued
NIAID E-213-2021-0-US-01 Aromatic Ring Substituted Amphiphilic Polymers As Drug Delivery Systems US 62/740,837 Abandoned
NCI E-266-2011-0-JP-33 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage JP DIV 2018-187094 Issued
NICHD E-552-2013-0-US-24 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE US CON 16/148,435 1106-01-10 Issued PDF
NIAID E-064-2016-1-US-07 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE US National Stage 16/089,993 11174292 Issued PDF
NIAID E-288-2016-0-US-03 Biomarkers And Vaccine Candidates For Filarial Parasites US National Stage 16/090,013 Abandoned
NCI E-008-2019-0-US-01 IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF US 62/738,317 Abandoned
NCI E-266-2011-0-US-32 T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE US DIV 16/144,226 11306131 Issued PDF
NHLBI E-196-2017-0-PCT-02 POLYDOPAMINE-ENCAPSULATED NANODIAMONDS AND METHODS PCT PCT PCT/US2018/053010 Expired
NIAID E-202-2018-0-US-01 USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTION US 62/737,899 Abandoned
NCI E-190-2014-0-US-15 VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS US CON 16/143,147 10588984 Issued PDF
NIAID E-233-2017-0-PCT-02 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES PCT PCT PCT/US2018/052968 Expired
NIAID E-233-2017-0-EP-04 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES EP National Stage 18786583.7 Pending
NIAID E-233-2017-0-CA-03 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES CA National Stage 3074914 Abandoned
NCATS E-116-2016-0-US-08 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE US National Stage 16/088,371 10919842 Issued PDF
NCATS E-036-2016-0-US-08 METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, FATIGUE, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS US National Stage 16/088,294 Abandoned
NCI E-215-2018-0-US-01 HALOGENATED 5-AZA-T-DCYD ANALOGS AND METHODS OF USE US 62/736,246 Abandoned
NCI E-182-2017-0-AU-03 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION AU National Stage 2018345400 Issued
NCI E-182-2017-0-PCT-02 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION PCT PCT PCT/US2018/052432 Expired
NCI E-182-2017-0-CN-05 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION CN National Stage 201880076862.9 Pending
NCI E-182-2017-0-CA-04 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION CA National Stage 3077595 Pending
NCI E-182-2017-0-SG-10 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION SG National Stage 11202003112Q Abandoned
NCI E-182-2017-0-KR-09 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION KR National Stage 2020-7012314 Pending
NIAID E-220-2018-0-US-01 HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE US 62/735,188 Abandoned
NCATS E-036-2016-0-JP-07 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders JP National Stage 2018-550327 Pending
NCI E-181-2017-0-TW-05 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS TW ORD 107133221 Issued
NCI E-181-2017-0-AR-03 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS AR ORD P180102695 Pending
NCI E-131-2018-0-US-01 Fully Human Antibody Targeting Human CD123 For Cancer Threpeutics Development US 62/734,106 Abandoned
NCI E-010-2019-0-US-01 Compositions And Methods For Modulation Of LMNA Expression US 62/734,196 Abandoned
NCI E-181-2017-0-IL-14 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS IL National Stage 273254 Issued
NCI E-181-2017-0-JP-16 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS JP National Stage 2020-516422 Issued
NCI E-181-2017-0-US-06 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS US ORD 16/135,231 11306132 Issued PDF
NCI E-133-2017-0-PCT-02 IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS PCT PCT PCT/US2018/051625 Expired
NCI E-181-2017-0-CN-10 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS CN National Stage 201880060535.4 Pending